Yair Molad Molad

Medicine & Life Sciences

1. Systemic Lupus Erythematosus 100%
2. Rheumatoid Arthritis 36%
3. Behcet Syndrome 34%
4. Antiphospholipid Syndrome 32%
5. Triggering Receptor Expressed on Myeloid Cells-1 27%
6. L-Selectin 25%
7. Neutrophils 23%
8. tocilizumab 22%
9. Antirheumatic Agents 21%
10. Vasculitis 18%
11. Autoantibodies 17%
12. HLA-B5 antigen 17%
13. CF101 16%
14. Integrins 16%
15. Lupus Coagulation Inhibitor 16%
16. Serum 15%
17. Congenital heart block 13%
18. Neutrophil Activation 13%
19. Antiphospholipid Antibodies 13%
20. Adenosine A3 Receptors 12%
21. Pregnancy 12%
22. Kidney 12%
23. Hydroxychloroquine 12%
24. Antibodies 11%
25. Methotrexate 11%
26. Biomarkers 11%
27. Rheumatology 11%
28. Israel 10%
29. Glycoproteins 10%
30. Immunoglobulin G 10%
31. Pregnancy Outcome 10%
32. Morbidity 10%
33. Blood Vessels 10%
34. Chemotactic Factors 10%
35. Cohort Studies 9%
36. Neonatal Systemic lupus erythematosus 9%
37. Colchicine 9%
38. Autoantigens 8%
39. Therapeutics 8%
40. Subcutaneous Injections 8%
41. Safety 8%
42. Chronic Renal Insufficiency 8%
43. edratide 8%
44. Familial Mediterranean Fever 8%
45. Mortality 8%
46. Complement Component 7 Deficiency 7%
47. Anti-Inflammatory Agents 7%
48. SS-A antibodies 7%
49. Jews 7%
50. Complement C7 7%